There's no disguising the fact that once-promising drugs for treating Alzheimer's and other forms of dementia, which together affect 5 million people in the U.S., have fizzled pretty dismally in recent months. According to MSN Money, 150 different companies are working on Alzheimer's drugs, and recent disappointments in several of the drugs' efficacy have some companies beginning to wonder if the research cost-effective (the article goes on to outline some of the bigger clinical trial failures i...
There's no disguising the fact that once-promising drugs for treating Alzheimer's and other forms of dementia, which together affect 5 million people in the U.S., have fizzled pretty dismally in recent months. According to MSN Money, 150 different companies are working on Alzheimer's drugs, and recent disappointments in several of the drugs' efficacy have some companies beginning to wonder if the research cost-effective (the article goes on to outline some of the bigger clinical trial failures i...
Share this Article
Recommended